Dr. Klausner Co-Chairs Committee Preparing NAS Terrorism Report

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 3
Volume 11
Issue 3

WASHINGTON-A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

WASHINGTON—A National Academy of Sciences (NAS) committee expects to issue a report in June on terrorism that will provide the federal government with a road map for the use of science and technology in all aspects of counterterrorism, Richard D. Klausner, MD, former National Cancer Institute (NCI) director, told ONI.

Dr. Klausner and Lewis M. Branscomb, PhD, Albert Pratt Public Service Professor at Harvard University’s John F. Kennedy School of Government, co-chair the committee. About 150 outside experts and consultants are contributing to the effort, which is expected to inform the decision-making process for the fiscal year 2004 budget.

In addition to his NAS commitment, Dr. Klausner continues to pursue research part time at NCI. He resigned as director last fall after more than 6 years in the post. He originally left to head a new institute established by the Case Foundation of AOL founder Steven Case and his wife, but the Cases withdrew their commitment to the project.

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content